The IV STING agonist, TAK-676, enhances immune-mediated anti-tumor activity of radiation in syngeneic mouse models

被引：0
|
作者：
Appleman, Vicky A. [1 ]
Berger, Allison J. [1 ]
Roberts, Emily R. [1 ]
Maldonado-Lopez, Angel E. [1 ]
Ganno, Michelle L. [1 ]
Christensen, Camilla I. [1 ]
Hatten, Tiquella [1 ]
Sato, Yosuke [1 ]
Shaw, Michael H. [1 ]
Malek, Karim S. [1 ]
Lineberry, Neil B. [1 ]
Abu-Yousif, Adnan O. [1 ]
Gregory, Richard C. [1 ]
机构：
[1] Takeda Dev Ctr Amer Inc TDCA, Lexington, MA USA
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3448
引用
收藏
页数：1
相关论文
共 47 条
  • [41] Stabilized recombinant trefoil factor 2 (TFF2-CTP) enhances anti-tumor activity of PD-1 blockade in mouse models of colorectal cancer
    Kim, Woosook
    Fu, Na
    Duddempudi, Phaneendra
    Dubeykovskaya, Zinaida
    Almo, Steven
    Guha, Chandan
    Lederman, Seth
    Wang, Timothy
    CANCER RESEARCH, 2020, 80 (16)
  • [42] OCT-598, a novel EP2/EP4 dual antagonist, promotes anti-tumor immune responses in syngeneic mouse tumor models in combination with standard-of-care chemo- and immunotherapies
    Lee, Youngrae
    Baek, Sujeong
    Kim, Dong Kwon
    Lee, Yeri
    Kim, Donggeon
    Jo, Seongin
    Lim, Sang Kyun
    Shin, Young Sook
    Kwon, Soonsang
    Yang, Seung Min
    Kim, Young Taek
    Kang, Seong-San
    Synn, Chun-Bong
    Na, Kwangmin
    Kim, Mi Hyun
    Han, Heekyung
    Han, Yu Jin
    Lee, Sungwoo
    Kim, Jae Hwan
    Yun, Mi Ran
    Byeon, Youngseon
    Kim, Young Seob
    Lee, Ji Yun
    Lee, Jii Bum
    Kim, Chang Gon
    Hong, Min Hee
    Lim, Sun Min
    Pyo, Kyoung-Ho
    Cho, Byoung Chul
    Yoon, Taeyoung
    CANCER RESEARCH, 2023, 83 (07)
  • [43] Targeting regulatory T cells by E7777 enhances CD8 T-cell-mediated anti-tumor activity and extends survival benefit of anti-PD-1 in solid tumor models
    Mahdi, Haider S.
    Woodall-Jappe, Mary
    Singh, Preeti
    Czuczman, Myron S.
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [44] Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12-and interferon β-mediated suppression of immune checkpoint receptor expression
    Jeon, Donghwan
    McNeel, Douglas G.
    ONCOIMMUNOLOGY, 2022, 11 (01):
  • [45] Ex-vivo inhibition of CBL-B with a novel small molecule inhibitor, NX-0255, enhances persistence and anti-tumor activity of adoptively transferred CD8+T cells in mouse tumor models
    Gallotta, Marilena
    Romo, Jose Gomez
    Borodovsky, Alexandra
    Tenn-McClellan, Austin
    Stokes, Jennifer
    Gosling, Jennifa
    Hansen, Gwenn M.
    Sands, Arthur
    Rountree, Ryan
    Guiducci, Cristiana
    CANCER RESEARCH, 2022, 82 (12)
  • [46] BND-22, a first-in-class, anti-ILT2 monoclonal antibody inhibits the immunosuppressive effects of HLA-G and enhances anti-tumor activity of immune cells in preclinical in vitro, ex vivo, and in vivo models
    Mandel, Ilana
    Haves, Dana
    Goldshtein, Ilana
    Peretz, Tsuri
    Alishekevitz, Dror
    Sapir, Yair
    Hashmueli, Sharon
    Friedman, Itay
    Ben Moshe, Tehila
    CANCER RESEARCH, 2020, 80 (16)
  • [47] IMT030122, A novel engineered EpCAM/CD3/4-1BB tri-specific antibody, enhances T-cell recruitment and demonstrates anti-tumor activity in mouse models of colorectal cancer
    Shen, Jianbo
    Qian, Niliang
    Xu, Guili
    Dou, Xiaoqian
    An, Ying
    Yang, Cuima
    Liu, Yujie
    Liu, Yunhui
    Pan, Xiujie
    Wang, Jingjing
    Bai, Guijun
    Chen, Hao
    Zhu, Xiaolin
    Gao, Xin
    Zhou, Guoxiong
    Xu, Qinzhi
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2024, 137
12345